APACC 2026 | Professor Eric Chow: Addressing Antimicrobial Resistance and Adherence Challenges — Analysis of Evidence Base and Implementation Barriers of DoxyPEP for STI Prevention 

APACC 2026 | Professor Eric Chow: Addressing Antimicrobial Resistance and Adherence Challenges — Analysis of Evidence Base and Implementation Barriers of DoxyPEP for STI Prevention 

The 11th Asia-Pacific AIDS & Co-infections Conference (APACC 2026) was successfully held in Tokyo, Japan. The prevention and control of sexually transmitted infections (STIs) has emerged as one of the most heated topics at the conference. To sort out current cutting-edge prevention and control strategies, Infectious Disease Frontier invited Professor Eric Chow from the Melbourne Sexual Health Centre, Monash University, for an exclusive in-depth interview.
EHA Echoes | Professor Xiaofan Zhu’s Team Showcases Breakthroughs in Pediatric Hematology with 1 Oral Presentation and 4 Poster Presentations

EHA Echoes | Professor Xiaofan Zhu’s Team Showcases Breakthroughs in Pediatric Hematology with 1 Oral Presentation and 4 Poster Presentations

As the Nordic summer welcomed the global hematology community, the 2026 European Hematology Association (EHA 2026) Congress was held in Stockholm, Sweden, from June 11–14. During this year's meeting, the pediatric hematology team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), led by Professor Xiaofan Zhu, presented five cutting-edge studies, including one oral presentation and four poster presentations.
EHA Echoes | Professor Haiwen Huang Explores New Insights into Lymphoma Etiology and a Safer, High-Efficacy Treatment Strategy

EHA Echoes | Professor Haiwen Huang Explores New Insights into Lymphoma Etiology and a Safer, High-Efficacy Treatment Strategy

At the 2026 European Hematology Association (EHA) Congress, Chinese investigators once again showcased their contributions to lymphoma research. Professor Haiwen Huang and colleagues from The First Affiliated Hospital of Soochow University presented two studies in the poster session. One employed Mendelian randomization to systematically investigate the causal relationship between genetically predicted viral infections and the risk of lymphoma across multiple subtypes. The other reported results from a Phase III multicenter trial evaluating a liposomal mitoxantrone hydrochloride-based CMOP±R regimen as first-line therapy for non-Hodgkin lymphoma (NHL).
EHA Reflections | Hematology Frontier | Young EHA Best Abstract Award: Professor Hu Xiaoxia and Dr. Zhang Ao Move the Frontline Forward with a Proactive Strategy for Post-Transplant EBV Management

EHA Reflections | Hematology Frontier | Young EHA Best Abstract Award: Professor Hu Xiaoxia and Dr. Zhang Ao Move the Frontline Forward with a Proactive Strategy for Post-Transplant EBV Management

At the 2026 European Hematology Association (EHA) Congress, a multicenter study led by Professor Hu Xiaoxia's team from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, was selected for an oral presentation and received the Young EHA Best Abstract Award. Addressing the longstanding challenge of Epstein–Barr virus (EBV) management following antithymocyte globulin (ATG)-based allogeneic hematopoietic cell transplantation (allo-HCT), the investigators proposed an innovative strategy of early prophylactic rituximab. The study demonstrated that this approach significantly reduced the incidence of EBV infection and post-transplant lymphoproliferative disorder (PTLD) without compromising long-term immune reconstitution, representing a fundamental shift from reactive management to proactive prevention. During the congress, Hematology Frontier interviewed first author Dr. Zhang Ao to discuss the clinical rationale, mechanisms underlying the multiple clinical benefits, and future directions for optimizing this strategy.
CSCO Leukemia Young Committee Perspectives | Bringing the Latest AML Advances from EHA 2026 Back to China 

CSCO Leukemia Young Committee Perspectives | Bringing the Latest AML Advances from EHA 2026 Back to China 

The 2026 European Hematology Association (EHA) Congress in Stockholm has concluded, unveiling a series of important advances in acute myeloid leukemia (AML). To help clinicians rapidly interpret the meeting's most impactful findings, the inaugural CSCO Leukemia Young Committee Perspectives webinar was held on June 14 through a collaboration between the CSCO Leukemia Youth Committee and Hematology Frontier. The program was chaired by Professor Qiu Shaowei, Chair of the CSCO Leukemia Committee Youth Group from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS). Joining the discussion were Professor Pei Shanzhan from the First Affiliated Hospital, Zhejiang University School of Medicine and Liangzhu Laboratory, Professor Tang Feifei from Peking University People's Hospital, and Professor Cao Yigeng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS). Together, they provided an in-depth review of the latest AML research presented at EHA 2026, highlighting its clinical significance and future implications.
EHA Reflections | Hematology Frontier | Professor Song Qingxiao: Breaking New Ground Through Cellular Metabolism—7-Ketocholesterol Offers a Precision Strategy for Steroid-Refractory Acute GVHD

EHA Reflections | Hematology Frontier | Professor Song Qingxiao: Breaking New Ground Through Cellular Metabolism—7-Ketocholesterol Offers a Precision Strategy for Steroid-Refractory Acute GVHD

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains one of the greatest clinical challenges following allogeneic hematopoietic stem cell transplantation (allo-HSCT). At the 2026 European Hematology Association (EHA) Congress, Professor Song Qingxiao from the Second Affiliated Hospital of Army Medical University presented an oral presentation reporting his team's latest discoveries on the pathogenesis of SR-aGVHD. The study demonstrated that 7-ketocholesterol (7-KC) can restore steroid sensitivity by reshaping T-cell lineage metabolism, providing a novel strategy for pre-transplant risk stratification and individualized intervention. During the meeting, Hematology Frontier interviewed Professor Song to discuss the clinical significance of these findings and their potential to overcome one of the most difficult barriers in SR-aGVHD management.
APPLE 2026 | Academician Jia Fan Invites You to APPLE 2026 in Shanghai: Witness China’s Growing Global Leadership in Liver Cancer and Explore AI-Driven Innovation 

APPLE 2026 | Academician Jia Fan Invites You to APPLE 2026 in Shanghai: Witness China’s Growing Global Leadership in Liver Cancer and Explore AI-Driven Innovation 

From July 3–5, 2026, the 16th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2026) will be held in Shanghai. Initiated by the Asia-Pacific Primary Liver Cancer Expert Association (APPLE), supported by the Shanghai Xinxin Medical Technology Development Foundation, and hosted by Zhongshan Hospital, Fudan University, the meeting will focus on the theme "Frontiers in the Diagnosis and Treatment of Primary Liver Cancer in the Era of Artificial Intelligence." Bringing together leading liver cancer experts from the Asia-Pacific region, Europe, and North America, APPLE 2026 will explore emerging strategies for liver cancer prevention and treatment. Following previous editions in 2012 and 2022, this marks the third time APPLE has been hosted in Shanghai, highlighting China's remarkable progress in healthcare, scientific research, and innovation over the past decade. Ahead of the meeting, Oncology Frontier spoke with Congress President Academician Jia Fan of Zhongshan Hospital, Fudan University, who reflected on APPLE's evolution, discussed the changing role of Chinese liver cancer specialists on the global stage, and shared his vision for how artificial intelligence (AI) will transform liver cancer care. Stay tuned for this landmark event.
ASCO 2026 | Prof. Li Mao: Ensartinib’s Global Strategy in the Intensifying ALK+ NSCLC Landscape

ASCO 2026 | Prof. Li Mao: Ensartinib’s Global Strategy in the Intensifying ALK+ NSCLC Landscape

On-site at the 2026 ASCO Annual Meeting, the targeted therapy landscape for ALK-positive non-small cell lung cancer (NSCLC) is witnessing intense competition, with multiple frontline updates from cutting-edge studies reshaping the global dynamics. As a pioneering Chinese homegrown innovative drug making its way onto the world stage, how can ensartinib—Betta Pharmaceuticals' proprietary ALK inhibitor—demonstrate its core value amidst formidable international rivals? MediaMedic had the privilege of an exclusive on-site interview with Professor Li Mao, President of R&D and Chief Medical Officer at Betta Pharmaceuticals, a seasoned leader deeply engaged in precision oncology, to deconstruct ensartinib's distinctive pathway to differentiation and global breakthrough. ADD HASHTAGS
ASCO 2026 | Prof. Kohei Shitara: T-DXd Establishes the New Standard for Second-Line HER2-Positive Advanced Gastric Cancer, with China’s Contributions Driving Global Progress

ASCO 2026 | Prof. Kohei Shitara: T-DXd Establishes the New Standard for Second-Line HER2-Positive Advanced Gastric Cancer, with China’s Contributions Driving Global Progress

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 29 to June 2, 2026, showcased several practice-changing advances in oncology. Among the highlights, Prof. Kohei Shitara from the National Cancer Center Hospital East, Japan, presented additional health-related quality of life (HRQoL) data from the landmark DESTINY-Gastric04 trial, further demonstrating the benefits of trastuzumab deruxtecan (T-DXd) in preserving patients' quality of life.
ASCO 2026 | Prof. Xiaotian Zhang and Prof. Yelena Janjigian: The DESTINY-Gastric Program Reshapes HER2-Targeted Therapy in Gastric Cancer as Chinese and U.S. Experts Discuss the Next Chapter

ASCO 2026 | Prof. Xiaotian Zhang and Prof. Yelena Janjigian: The DESTINY-Gastric Program Reshapes HER2-Targeted Therapy in Gastric Cancer as Chinese and U.S. Experts Discuss the Next Chapter

The landmark results of the DESTINY-Gastric04 (DG04) trial have firmly established trastuzumab deruxtecan (T-DXd) as the missing piece in second-line HER2-targeted treatment for gastric cancer. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the DESTINY-Gastric03 (DG03) study was also unveiled, highlighting the promising potential of T-DXd in the first-line setting. As T-DXd moves from later-line therapy toward frontline treatment for HER2-positive gastric cancer, an increasing number of patients stand to benefit.